Search research articles
Contact Us
Filters
Showing results (471-480 of 480) with videos related to
Page
of 48
Sort By:
You have reached the last page of results.
This site can display upto 480 results.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
November 14, 1997
Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile
S K Balani, X Xu, V Pratha, et al.
Bioorganic & Medicinal Chemistry Letters
|
January 1, 1999
L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor
P E Sanderson, K J Cutrona, B D Dorsey, et al.
Journal of Medicinal Chemistry
|
February 17, 1998
Discovery and development of the novel potent orally active thrombin inhibitor N-(9-hydroxy-9-fluorenecarboxy)prolyl trans-4-aminocyclohexylmethyl amide (L-372,460): coapplication of structure-based design and rapid multiple analogue synthesis on solid support
S F Brady, K J Stauffer, W C Lumma, et al.
Journal of Medicinal Chemistry
|
September 9, 2000
Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors
B D Dorsey, C McDonough, S L McDaniel, et al.
The British Journal of Surgery
|
April 5, 2020
Prognostic model for identifying candidates for hepatectomy among patients with hepatocellular carcinoma and hepatic vein invasion
X-P Zhang, K Wang, Y-Z Gao, et al.
Journal of Medicinal Chemistry
|
November 7, 1998
Efficacious, orally bioavailable thrombin inhibitors based on 3-aminopyridinone or 3-aminopyrazinone acetamide peptidomimetic templates
P E Sanderson, T A Lyle, K J Cutrona, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 11, 2022
Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial
Xuan Ying Poh, Chee Wah Tan, I Russel Lee, et al.
Vaccine
|
September 6, 2024
Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial
Xuan Ying Poh, Anthony Torres-Ruesta, Terence Yoong, et al.
Ebiomedicine
|
August 13, 2024
First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial
Xuan Ying Poh, I Russel Lee, Chee Wah Tan, et al.
Journal of Medical Virology
|
October 28, 2022
Efficient recall of SARS-CoV-2 variant-reactive B cells and T responses in the elderly upon heterologous mRNA vaccines as boosters
Angeline Rouers, Nathan Wong, Yun Shan Goh, et al.
Page
of 48
Search research articles
Search
Showing results (471-480 of 480) with videos related to
Sort By:
Page
of 48
You have reached the last page of results.
This site can display upto 480 results.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
November 14, 1997
Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile
S K Balani, X Xu, V Pratha, et al.
Bioorganic & Medicinal Chemistry Letters
|
January 1, 1999
L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor
P E Sanderson, K J Cutrona, B D Dorsey, et al.
Journal of Medicinal Chemistry
|
February 17, 1998
Discovery and development of the novel potent orally active thrombin inhibitor N-(9-hydroxy-9-fluorenecarboxy)prolyl trans-4-aminocyclohexylmethyl amide (L-372,460): coapplication of structure-based design and rapid multiple analogue synthesis on solid support
S F Brady, K J Stauffer, W C Lumma, et al.
Journal of Medicinal Chemistry
|
September 9, 2000
Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors
B D Dorsey, C McDonough, S L McDaniel, et al.
The British Journal of Surgery
|
April 5, 2020
Prognostic model for identifying candidates for hepatectomy among patients with hepatocellular carcinoma and hepatic vein invasion
X-P Zhang, K Wang, Y-Z Gao, et al.
Journal of Medicinal Chemistry
|
November 7, 1998
Efficacious, orally bioavailable thrombin inhibitors based on 3-aminopyridinone or 3-aminopyrazinone acetamide peptidomimetic templates
P E Sanderson, T A Lyle, K J Cutrona, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 11, 2022
Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial
Xuan Ying Poh, Chee Wah Tan, I Russel Lee, et al.
Vaccine
|
September 6, 2024
Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial
Xuan Ying Poh, Anthony Torres-Ruesta, Terence Yoong, et al.
Ebiomedicine
|
August 13, 2024
First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial
Xuan Ying Poh, I Russel Lee, Chee Wah Tan, et al.
Journal of Medical Virology
|
October 28, 2022
Efficient recall of SARS-CoV-2 variant-reactive B cells and T responses in the elderly upon heterologous mRNA vaccines as boosters
Angeline Rouers, Nathan Wong, Yun Shan Goh, et al.
Page
of 48